寻百会的动态

https://lnkd.in/grD8nmmj In these four publications this year we established the central role of TGFB2 in oncology

Roche today announced the acquisition of Poseida Therapeutics, which will allow us to develop a portfolio of 2nd generation donor-derived, off-the-shelf (allogeneic) CAR-Ts across several therapeutic areas including malignant hematology (NHL, MM) and solid tumors, but also for autoimmune diseases, such as MS or SLE.?An approach which is complementary to taking our CD20/CD19xCD3 bispecifics into autoimmune diseases.

Thrilled to share Roche’s acquisition of Poseida Therapeutics, Inc. This allows us to access Poseida’s R&D portfolio of clinical-stage allogeneic CAR-T treatments and earlier preclinical programs that have a great potential to become transformative medicines and treat patients with severe diseases such as hematological malignancies, solid tumors and autoimmune diseases.? A big thanks to the dedicated team at Roche and the relentless efforts that went into making this happen. It was a truly rewarding experience to lead the commercial subteam through this due diligence which was instrumental in assessing and ultimately securing this groundbreaking technology. Together, we are poised to make significant advancements in the treatment landscape and bring hope to many patients worldwide. ?? #Roche #Partnerships #BusinessDevelopment #CART #Biotech #Innovation #Healthcare

I am very excited to share that Roche has entered into a definitive agreement to acquire Poseida Therapeutics, Inc., enhancing our mission to address significant unmet medical needs. This strategic move is perfectly aligned with our ambition to join forces with others to drive innovation across critical therapeutic areas, including, oncology, immunology, and neurology. Our unwavering commitment to advancing innovative medicines fuels our deep interest in cell therapy, a promising field in disease treatment. Access to Poseida Therapeutics’ “off-the-shelf” CAR-T platform, a range of potentially first and best-in-class therapies across several indications, combined with both companies’ collective expertise and capabilities, holds immense potential to transform patient care. This acquisition uniquely positions Roche at the forefront of the new field of donor-derived off-the-shelf cellular therapeutics. A huge thank you to the exceptional teams who have worked tirelessly to bring this to life! Read more here: https://lnkd.in/es8HGGRu #RocheInnovation #Celltherapy #Oncology

T-cells recognize foreign matter by using T-cell receptors (TCR) to bind to human leukocyte antigens (HLAs) and work to remove these foreign cells (e.g., virus-infected, malignant, cancerous cells). The promise of T-cell receptor therapy is that you can use this principle to precisely target specific HLAs in a particular disease and perform targeted treatment (for example, hard-to-treat cancers) The problem though is that there are multiple HLAs, even for the same disease amongst different patient populations, resulting in need for libraries of HLAs that every patient with that disease. Thereafter, the treatment needs to be tested to make sure it is safe, validated that it works effectively and manufactured at scale. At #ESMO24, my colleagues presented Anocca's solution: A platform that systematically recreates human T-cell biology to map HLAs, generate therapeutic TCR libraries and manufactures solutions for solid cancers. Here we show data from our lead TCR-T product, KRAS-G12V (a driver in pancreatic, lung and colon cancers) that is advancing to clinical trials. Check out the poster! https://lnkd.in/exUBSvQU

Ongoing innovations in cell therapy have the potential to bring substantial treatment benefits to people with cancer and other diseases. Poseida Therapeutics, Inc. has been a valued partner to Roche and Genentech over the past couple of years, and I'm thrilled that we will be bringing new assets to our portfolio and great people onto our teams. We look forward to driving further progress in allogeneic cell therapy by fully combining the technology innovation of Poseida with the global scale and broad disease-based expertise of Roche. By joining forces, we have superb potential to deliver multiple transformative medicines across key hematologic cancers, solid tumors, and autoimmune diseases. I can’t wait to see what we’ll accomplish together! Read more here: https://lnkd.in/ga2tkdCz #RocheInnovation #Celltherapy #Oncology

Our CSO Hugh Salter along with our CMO Zahid Bashir, MBBS, MSc Oncology, Director of Clinical Development Sheila Forsman and Clinial Science Lead Rehab Alnabhan presented preclinical data at #ESMO24 on our TCR-T cell therapies targeting mutated KRAS. The poster introduced our novel platform, which systematically recreates human T-cell biology to map targets and generate therapeutic TCR libraries to enable in-house manufacturing of a deep pipeline of products that addresses a broad range of hard-to-treat solid tumour cancers. The data showcased the development of our lead TCR-T product targeting KRAS-G12V, a critical driver in cancers like pancreatic, lung, and colon, that is advancing toward clinical trials. We were pleased to have been shortlisted for best poster in the section (investigational immunotherapy)! ??? See the poster: https://lnkd.in/exUBSvQU #biotech #pharma #celltherapy #innovation #TCR ESMO - European Society for Medical Oncology

Our commitment to innovation drives us to discover and develop pioneering medicines that offer substantial benefits to patients. We are very excited to share today’s announcement that we entered into a definitive agreement to acquire Poseida Therapeutics, Inc. The acquisition supports Roche’s Pharma Strategy and allows for a range of potentially first and best-in-class therapies across oncology, immunology, and neurology, uniquely positioning Roche in the new field of donor-derived off-the-shelf cell therapies. #RocheInnovation #Celltherapy #Oncology

A move to 1st line that looks to change how we treat mCRC. There has not been a new 1st line therapy in over 2 decades. Add to the equation that Cardiff Oncology's Onvansertib is very well tolerated and oral, if the results from CRDF-004 fall in line with the previous mountain of P2 and preclinical data, then mCRC patients will be celebrating everywhere. Interim results should be released sometime before end of year. #letsGo #CancerInnovation https://lnkd.in/gYb8bV-g

Join the Leaders in Oncology Imaging for an Exclusive Webinar! On October 16th at 2:00 PM ET, Imaging Endpoints and Fierce Bio are hosting a must-attend webinar: "How Does Imaging Support the Development of New Therapeutics? A Focus on ADC and Radioisotope Therapy." Discover how advanced imaging is playing a critical role in developing targeted cancer therapies like Antibody-Drug Conjugates (ADCs) and Radioisotope Therapy (RIT). With IE's extensive experience in clinical trials involving these therapies, we’ll share key insights into the significant impact of imaging for assessing the efficacy and safety of these treatments. What You’ll Learn: -Strategies for developing ADCs and RIT -The role of imaging in accelerating clinical trials and drug approval -Why protocol design and charter development are key for bridging the gap between early-phase trials and registration trials Expert Panel Includes: -Elliot K. Fishman, M.D. (Johns Hopkins), global leader in diagnostic and 3D imaging -Steven P. Rowe, M.D., Ph.D. (UNC School of Medicine, Molecular Imaging and Therapeutics Division Chief), expert in molecular imaging and theranostics -Daejin Abidoye, M.D. (Vice President, Head of Solid Tumors, AbbVie), research and development in leader and expert in antibody drug conjugate (ADC) technologies and immunotherapies -Ron Korn, M.D., Ph.D. (Imaging Endpoints), renown leader in clinical trial imaging Register now: https://lnkd.in/gEvVCTga #Webinar #ClinicalTrials #OncologyResearch #ImagingEndpoints #ADC #RadioisotopeTherapy #CancerTreatment